MARKET

MGEN

MGEN

Miragen Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8660
-0.0367
-4.07%
Closed 16:00 10/22 EDT
OPEN
0.8800
PREV CLOSE
0.9027
HIGH
0.8900
LOW
0.8100
VOLUME
65.69K
TURNOVER
--
52 WEEK HIGH
4.960
52 WEEK LOW
0.6501
MARKET CAP
26.89M
P/E (TTM)
-0.6706
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MGEN News

  • miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call
  • GlobeNewswire.19h ago
  • MiRagen up 25% premarket on positive MRG-110 data
  • seekingalpha.6d ago
  • miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
  • GlobeNewswire.10/16 07:45
  • miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
  • Benzinga.10/16 07:00

More

Industry

Biotechnology & Medical Research
+0.44%
Pharmaceuticals & Medical Research
+0.60%

Hot Stocks

Name
Price
%Change

About MGEN

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
More

Webull offers Miragen Therapeutics Inc (MGEN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.